Novo Nordisk’s Bold Gambit: Price Cuts Spark Investor Debate
Published on 11/21/2025 at 08:57 | Redaktion boerse-global.de
The Danish pharmaceutical giant, once Europe’s most valuable company, now faces a critical inflection point. In a dramatic strategic pivot, Novo Nordisk is implementing aggressive price reductions for its blockbuster weight-loss drugs. This move places investors at a crossroads: is this the catalyst for renewed mass-market expansion, or the beginning of a dangerous erosion of profitability?
CEO Mike Doustdar has signaled a fundamental change in direction, prioritizing sales volume over profit margins. The company is launching an introductory offer for Wegovy at $199, a clear offensive against rivals like Eli Lilly and the burgeoning market for compounded medications. This aggressive pricing is widely seen as a direct countermeasure to the “TrumpRx” Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
